Real world predictors of response and 24-month survival in high-grade TP53-mutated myeloid neoplasms

Lung, Respiratory and Thoracic Cancer

Impact of EML4-ALK variants and co-occurring TP53 mutations on duration of first-line ALK tyrosine kinase inhibitor treatment and overall survival in ALK fusion-positive NSCLC: Real-world outcomes from the GuardantINFORM database

J Thorac Oncol

Parikh K, Dimou A, Leventakos K, Mansfield AS, Shanshal M, Wan Y, Lin HM, Vincent S, Elliott J, Bonta IR

doi: 10.1016/j.jtho.2024.07.009

Leukemia

The initial molecular response predicts the deep molecular response but not treatment-free remission maintenance in a real-world chronic myeloid leukemia cohort

Haematologica

Saugues S, Lambert C, Daguenet E, Roth-Guepin G, Huguet F, Cony-Makhoul P, Ansah HJ, Escoffre-Barbe M, Turhan A, Rousselot P, Tchirkov A, Hamroun D, Hermet E, Pereira B, Berger MG

doi: 10.3324/haematol.2023.284860

ASCO 2024

Genitourinary Cancer

OASIS: Rapid and deep responses to apalutamide plus ADT significantly improved survival in patients with mHSPC treated in real-world practice

Leukemia

Cytarabine dose intensification improves survival in older patients with secondary/high-risk acute myeloid leukemia in matched real-world versus clinical trial data

Leuk Lymphoma

Abé C, Keto J, Lilja M, Konradsen M, Mesterton J, Höglund M, Lazarevic V, Lehmann S, Juliusson G

doi: 10.1080/10428194.2024.2363430

Myelodysplastic syndromes

Clinical interrogation of TP53 aberrations and its impact on survival in patients with myeloid neoplasms

Haematologica

Senapati J, Loghavi S, Garcia-Manero G, Tang G, Kadia T, Short NJ, Abbas HA, Arani N, DiNardo CD, Borthakur G, Pemmaraju N, Oran B, Shpall E, Popat U, Champlin R, Pierce S, Arora S, Issa G, Yilmaz M, Patel K, Takahashi K, Montalban-Bravo G, Hammond D, Haddad FG, Ravandi F, Kantarjian HM, Daver NG

doi: 10.3324/haematol.2024.286465

ASH 2024

Leukemia

Real-world evidence confirms gilteritinib as an effective treatment option for R/R FLT3-mutated AML

ASH 2024

Lymphoma

Liso-cel is effective and safe in a broad real-world population of R/R LBCL^a patients, including second-line setting and secondary CNS involvement

SPECIAL REPORT

Breast Cancer

Results of TRODELVY^® real-world data

SPECIAL REPORT

Lymphoma

Related content

Impact of EML4-ALK variants and co-occurring TP53 mutations on duration of first-line ALK tyrosine kinase inhibitor treatment and overall survival in ALK fusion-positive NSCLC: Real-world outcomes from the GuardantINFORM database

The initial molecular response predicts the deep molecular response but not treatment-free remission maintenance in a real-world chronic myeloid leukemia cohort

OASIS: Rapid and deep responses to apalutamide plus ADT significantly improved survival in patients with mHSPC treated in real-world practice

Cytarabine dose intensification improves survival in older patients with secondary/high-risk acute myeloid leukemia in matched real-world versus clinical trial data

Clinical interrogation of TP53 aberrations and its impact on survival in patients with myeloid neoplasms

Real-world evidence confirms gilteritinib as an effective treatment option for R/R FLT3-mutated AML

Liso-cel is effective and safe in a broad real-world population of R/R LBCLa patients, including second-line setting and secondary CNS involvement

Results of TRODELVY® real-world data

Real-World Comparison of YESCARTA® and Liso-Cel in 2L+ Among Patients with R/R DLBCL and HGBL

Liso-cel is effective and safe in a broad real-world population of R/R LBCL^a patients, including second-line setting and secondary CNS involvement

Results of TRODELVY^® real-world data

Real-World Comparison of YESCARTA^® and Liso-Cel in 2L+ Among Patients with R/R DLBCL and HGBL